BIOAXONE BIOSCIENCES, INC.

BioAxone BioSciences is a clinical-stage biopharmaceutical company focused on unmet needs in central nervous system disease and ophthalmology. The company leverages decades of pioneering research into axon regeneration and neuronal signaling pathways — specifically the Rho/ROCK signaling axis — to develop a pipeline of therapeutic drugs for conditions including spinal cord injury, stroke, cerebral cavernous malformations (CCMs), and glaucoma. BioAxone's lead drug VX-210 was licensed to Vertex Pharmaceuticals for a Phase 2b/3 clinical trial in acute traumatic cervical spinal cord injury. Beyond VX-210, the company is advancing selective ROCK2 inhibitors designed to extend the window of treatment after spinal cord injury, repair blood-brain barrier disruption, and promote functional recovery.